display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR positive - L2 - all population
phosphoinositide 3-kinase (PI3K) inhibitor
buparlisib based treatment
buparlisib plus fulvestrant BELLE-2 ...

Study type: